Amalgamated Bank Sells 491 Shares of Qiagen (NYSE:QGEN)

Amalgamated Bank reduced its position in shares of Qiagen (NYSE:QGEN) by 4.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,633 shares of the company’s stock after selling 491 shares during the period. Amalgamated Bank’s holdings in Qiagen were worth $530,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. TD Asset Management Inc purchased a new position in Qiagen in the second quarter worth $2,103,000. Edgestream Partners L.P. purchased a new position in Qiagen in the first quarter worth $1,492,000. Raymond James & Associates lifted its stake in Qiagen by 12.7% in the second quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock worth $22,289,000 after purchasing an additional 61,008 shares during the last quarter. Barings LLC bought a new stake in Qiagen in the second quarter worth $12,463,000. Finally, Sei Investments Co. lifted its stake in Qiagen by 19.7% in the second quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock worth $69,702,000 after purchasing an additional 278,930 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of QGEN opened at $41.27 on Friday. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.44. The stock has a market cap of $9.42 billion, a PE ratio of 105.82, a P/E/G ratio of 3.24 and a beta of 0.41. The firm has a 50-day simple moving average of $43.85 and a two-hundred day simple moving average of $43.76. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.46.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on QGEN. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Robert W. Baird increased their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.